ANI Pharma (ANIP) Tops Q3 EPS by 1c

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.09, $0.01 better than the analyst estimate of $1.08. Revenue for the quarter came in at $38.5 million versus the consensus estimate of $34.34 million.

GUIDANCE:

ANI Pharma sees FY2016 EPS of $4.00-$4.25, versus the consensus of $4.09. ANI Pharma sees FY2016 revenue of $128-134 million, versus the consensus of $126.1 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Lockheed Martin (LMT) Tops Q1 EPS by 59c, Beats on Revenue; Offers FY24 Guidance
• Kimberly-Clark (KMB) Tops Q1 EPS by 38c; updates outlook